Controversies in primary CNS lymphoma

ReferencesPapers of special note have been highlighted as: • of interest •• of considerable interest

• Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J. Clin. Oncol. 18, 3144–3150 (2000).
   PubMed Web of Science ®Google Scholar
• DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93–10. J. Clin. Oncol. 20, 4643–4648 (2002).
   Google Scholar
• O’Brien P, Roos D, Pratt G et al. Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J. Clin. Oncol. 18, 519–526 (2000).
   PubMed Web of Science ®Google Scholar
• Batchelor T, Carson K, O’Neill A et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96–07. J. Clin. Oncol. 21, 1044–1049 (2003).
   PubMed Web of Science ®Google Scholar
• Hoang-Xuan K, Taillandier L, Chinot O et al. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter Phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J. Clin. Oncol. 21, 2726–2731 (2003).
   PubMed Web of Science ®Google Scholar
• Abrey LE, Yahalom J, DeAngelis LM. Long-term survival in primary central nervous system lymphoma (PCNSL). J. Clin. Oncol. 16, 859–863 (1998).
   PubMed Web of Science ®Google Scholar
• Sandor V, Stark-Vancs V, Pearson D et al. Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J. Clin. Oncol. 16, 3000–3006 (1998).
   PubMed Web of Science ®Google Scholar
• Pels H, Schmidt-Wolf IG, Glasmacher A et al. Primary central nervous system lymphoma: results of a pilot and Phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J. Clin. Oncol. 21, 4489–4495 (2003).
   PubMed Web of Science ®Google Scholar
• Herrlinger U, Schabet M, Brugger W et al. German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. Ann. Neurol. 51, 247–252 (2002).
   PubMed Web of Science ®Google Scholar
• Abrey LE, Moskowitz CH, Mason WP et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J. Clin. Oncol. 21, 4151–4156 (2003).
   PubMed Web of Science ®Google Scholar
• DeAngelis LM, Yahalom J, Thaler HT, Kher U. Combined modality therapy for primary CNS lymphoma. J. Clin. Oncol.10, 635–643 (1992).
   PubMed Web of Science ®Google Scholar
• Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H et al. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J. Clin. Oncol. 21, 4483–4488 (2003).
   PubMed Web of Science ®Google Scholar
• Lippens RJ, Winograd B. Methotrexate concentration levels in the cerebrospinal fluid during high-dose methotrexate infusions: an unreliable prediction. Pediatr. Hematol. Oncol. 5, 115–124 (1988).
   PubMed Web of Science ®Google Scholar
• Vassal G, Valteau D, Bonnay M, Patte C, Aubier F, Lemerle J. Cerebrospinal fluid and plasma methotrexate levels following high-dose regimen given as a 3-hour intravenous infusion in children with non-Hodgkin’s lymphoma. Pediatr. Hematol. Oncol. 7, 71–77 (1990).
   PubMed Web of Science ®Google Scholar
• Tetef ML, Margolin KA, Doroshow JH et al. Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. Cancer Chemother. Pharmacol. 46, 19–26 (2000).
   PubMed Web of Science ®Google Scholar
• Omuro AMP, DeAngelis LM, Yahalom J, Abrey LE. Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up. Neurology 64, 69–74 (2005).
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Reni M, Pasini F et al. A multicenter study of treatment of primary CNS lymphoma. Neurology 58, 1513–1520 (2002).
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Batchelor T, Zucca E, Cavalli F, Armitage J. International Collaborative Group against primary CNS lymphomas. J. Clin. Oncol. 21, 1649–1650 (2003).
   PubMed Web of Science ®Google Scholar
• Bessell EM, Lopez-Guillermo A, Villa S et al. Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. J. Clin. Oncol. 20, 231–236 (2002).
   PubMed Web of Science ®Google Scholar
• Shibamoto Y, Hayabuchi N, Hiratsuka J et al. Is whole-brain irradiation necessary for primary central nervous system lymphoma? Patterns of recurrence after partial-brain irradiation. Cancer 97, 128–133 (2003).
   PubMed Web of Science ®Google Scholar
• McAllister LD, Doolittle ND, Guastadisegni PE et al. Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 46, 51–60 (2000).
   PubMed Web of Science ®Google Scholar
• O’Neill BP, Habermann TM, Witzig TE, Rodriguez M. Prevention of recurrence and prolonged survival in primary central nervous system lymphoma (PCNSL) patients treated with adjuvant high-dose methylprednisolone. Med. Oncol. 16, 211–215 (1999).
   PubMed Web of Science ®Google Scholar
• Pels H, Schulz H, Manzke O, Hom E, Thall A, Engert A. Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab. J. Neurooncol. 59, 213–216 (2002).
   PubMed Web of Science ®Google Scholar
• Schulz H, Pels H, Schmidt-Wolf I, Zeelen U, Germing U, Engert A. Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica 89, 753–754 (2004).
   PubMed Web of Science ®Google Scholar
• Enting RH, Demopoulos A, DeAngelis LM, Abrey LE. Salvage therapy for primary central nervous system lymphoma with a combination of rituximab and Temozolomide. Neurology 5, 901–903 (2004).
   Google Scholar
• Nakamura M, Shimada K, Ishida E, Konishi N. Histopathology, pathogenesis and molecular genetics in primary central nervous system lymphomas. Histol. Histopathol. 19, 211–219 (2004).
   Google Scholar
• Harada K, Nishizaki T, Kubota H, Harada K, Suzuki M, Sasaki K. Distinct primary central nervous system lymphoma defined by comparative genomic hybridization and laser scanning cytometry. Cancer Genet. Cytogenet.125, 147–150 (2001).
   Google Scholar
• Tilly H, Rossi A, Stamatoullas A et al. Prognostic value of chromosomal abnormalities in follicular lymphoma. Blood 84, 1043–1049 (1994).
   PubMed Web of Science ®Google Scholar
• Nakamura M, Kishi M, Sakaki T et al. Novel tumor suppressor loci on 6q22–23 in primary central nervous system lymphomas. Cancer Res. 63, 737–741 (2003).
   PubMedGoogle Scholar
• Braaten KM, Betensky RA, de Leval L et al. BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin. Cancer Res. 9, 1063–1069 (2003).
   PubMed Web of Science ®Google Scholar
• Rubenstein J, Shen A, Fridlyand J et al. Gene expression profile analysis of primary CNS lymphoma: class distinction and outcome prediction. Proc. Am. Assoc. Cancer Res. (2004).
   Google Scholar
• Abrey LE, Batchelor TT, Andres JM et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary central nervous system lymphoma. J. Clin. Oncol. (2005) (In Press).
   Google Scholar
• Nelson DF, Martz KL, Bonner H et al. Non-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int. J. Radiat. Oncol. Biol. Phys. 23, 9–17 (1992).
   PubMed Web of Science ®Google Scholar
• Abrey LE, Yahalom J, DeAngelis LM. Relapse and late neurotoxicity in primary central nervous system lymphoma. Neurology 48, 18 (1997).
   Google Scholar